Kaos Capital pushes for board changes at Capricor Therapeutics
Kaos Capital Ltd., a shareholder in Capricor Therapeutics Inc. (NASDAQ:CAPR), is demanding immediate board changes, including the nomination of two independent directors and the formation of an M&A and Strategic Alternatives Committee. The investment firm is pushing for a cash preservation plan, citing a significant decrease in Capricor's cash reserves and increased operating expenses. Kaos Capital also highlighted various legal issues faced by Capricor and is prepared to seek shareholder support if their demands are not met.
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’
On CNBC's "Halftime Report Final Trades," experts recommended ServiceNow, Vertex Pharmaceuticals, and Uber Technologies. ServiceNow was highlighted for its expanded partnership with Tech Mahindra on AI projects. Vertex Pharmaceuticals was noted for its strong Q2 earnings and raised FY2026 sales guidance, while Uber was featured for launching fully driverless Apollo Go robotaxis in Dubai with Baidu.
Zacks Research Upgrades Alexandria Real Estate Equities (NYSE:ARE) to "Hold"
Zacks Research has upgraded Alexandria Real Estate Equities (NYSE:ARE) from a "strong sell" to a "hold" rating, despite a consensus "Reduce" rating and a target price of $52.38 from other analysts. The company recently reported a significant EPS miss and a 13% year-over-year revenue decline. Insider trading activity was mixed, with the CFO selling shares and the Chairman purchasing shares, while institutional investors hold a substantial portion of the stock.
What is Zacks Research's Estimate for TSE:BHC Q3 Earnings?
Zacks Research has updated its Q3 2026 EPS estimate for Bausch Health Companies (TSE:BHC) to $1.44, a slight decrease from its previous forecast of $1.47. The firm also provided earnings estimates for several future quarters and full fiscal years. Despite the slight downward revision for Q3 2026, the company's shares are trading near a 12-month high, and analysts maintain a "Hold" rating on the stock.
Medical records, SSNs, and bank details exposed in CareCloud data breach
Healthcare technology company CareCloud has disclosed a data breach affecting over 3.75 million people, making it one of the largest healthcare data incidents this year. An unauthorized third party accessed one of its AWS environments, exfiltrating sensitive data including full names, SSNs, medical records, and financial details. The article advises affected individuals to take specific steps to protect themselves, such as changing passwords, enabling two-factor authentication, and monitoring for identity theft.
AbbVie will present 90% lung cancer response data; the treatment remains investigational
AbbVie announced it will present new data at the 2026 World Conference on Lung Cancer (WCLC) on its investigational lung cancer treatments. Key findings include a 90% objective response rate for ABBV-1480 plus chemotherapy in squamous NSCLC and promising data for telisotuzumab adizutecan (Temab-A) and ABBV-706. Despite positive data, the treatments remain investigational and are not yet approved by health authorities.
William Blair initiates Beta Bionics stock rating at Market Perform By Investing.com
William Blair has initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Market Perform rating, citing the company's iLet insulin pump's unique AID algorithm and strong revenue growth. Despite a recent earnings miss, Beta Bionics maintained its full-year outlook, and analysts highlighted its strong financial position with more cash than debt and upcoming entry into the patch pump market in 2027.
Alkermes ends Amneal VIVITROL supply pact without penalties
Alkermes plc and Amneal Pharmaceuticals LLC have terminated their Authorized Generic Product Supply Agreement for VIVITROL on July 6, 2026, without incurring penalties. The termination occurred because Amneal failed to meet certain terms and chose not to order batches. Both parties have released mutual claims, concluding the agreement that was originally signed in September 2025.
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC
Paralel Advisors LLC acquired 40,919 shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, valued at approximately $2.34 million, as institutional investors now collectively own 98.71% of the company's outstanding shares. BioMarin exceeded quarterly expectations with $1.20 EPS and $989.7 million in revenue, leading to a "Moderate Buy" consensus rating among analysts, despite mixed sentiment regarding recent acquisitions and future growth prospects. The company's stock opened at $67.68, near its 12-month high of $70.98, reflecting its strong financial performance and positive analyst upgrades.
NFJ Investment Group LLC Makes New $2.79 Million Investment in BioCryst Pharmaceuticals, Inc. $BCRX
NFJ Investment Group LLC has made a new investment of $2.79 million in BioCryst Pharmaceuticals, acquiring 278,792 shares, which represents a 0.11% stake in the company. Institutional investors collectively hold 85.88% of BioCryst Pharmaceuticals, and analysts maintain a "Moderate Buy" rating with a consensus price target of $20.60. BioCryst recently exceeded quarterly expectations, reporting $0.30 EPS against an expected $0.15 and revenues of $218.25 million, surpassing the forecast of $183.28 million.
Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Becton Dickinson (BDX) has completed patient enrollment for its PREVENT clinical trial, which evaluates Phasix Mesh for preventing incisional hernias. This milestone brings the trial closer to data readout and potential regulatory review for what the company considers a groundbreaking product in this category. The trial's success could significantly impact Becton Dickinson's future product portfolio and revenue in the surgical hernia prevention market.
Portfolio Design Labs LLC Takes $1.29 Million Position in Gilead Sciences, Inc. $GILD
Portfolio Design Labs LLC has acquired a new position of 10,178 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $1.29 million, during the second quarter. This move is part of a broader trend where other institutional investors have also increased their stakes in the biopharmaceutical company. Analysts currently rate GILD as a "Moderate Buy" with an average price target of $158.04, despite recent insider selling and mixed long-term earnings forecasts.
NFJ Investment Group LLC Invests $7.76 Million in West Pharmaceutical Services, Inc. $WST
NFJ Investment Group LLC has invested $7.76 million in West Pharmaceutical Services, Inc. by purchasing 21,614 shares. This move highlights institutional confidence, with analysts maintaining a "Moderate Buy" rating and Barclays recently upgrading the stock to "overweight" with a $400 target. West Pharmaceutical Services exceeded Q2 earnings expectations and offers an annualized dividend of $0.88 per share.
Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM
Silvant Capital Management LLC has acquired a new position of 79,562 shares in DexCom, Inc. (NASDAQ:DXCM) worth approximately $5.36 million during the second quarter. Other institutional investors have also adjusted their holdings in DexCom, which has an average analyst rating of "Moderate Buy" and a consensus target price of $88.71. The company recently reported strong quarterly earnings, beating analyst estimates, and has seen some insider selling activity.
6,796 Shares in Danaher Corporation $DHR Bought by Portfolio Design Labs LLC
Portfolio Design Labs LLC has acquired a new stake of 6,796 shares in Danaher Corporation (NYSE:DHR) during the second quarter, valued at approximately $1,295,000. Other institutional investors like BlackRock Inc. and Norges Bank also significantly increased their holdings in Danaher. The company's stock trading at $216.14, has a market cap of $151.94 billion, and recently topped earnings estimates with $1.94 EPS against a consensus of $1.85.
NFJ Investment Group LLC Buys New Stake in Aveanna Healthcare Holdings Inc. $AVAH
NFJ Investment Group LLC has acquired a new stake in Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), purchasing 312,997 shares valued at approximately $2.68 million during the second quarter. While institutional investors collectively own a significant portion of the company, major shareholders and insiders have recently sold substantial amounts of stock. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $11.78, following Aveanna's positive quarterly earnings report.
Portfolio Design Labs LLC Invests $1.35 Million in Stryker Corporation $SYK
Portfolio Design Labs LLC has invested approximately $1.35 million in Stryker Corporation, acquiring 4,281 shares during the second quarter. This move reflects a broader trend of institutional investors modifying their holdings in the medical technology company. Stryker, which recently reported strong quarterly earnings and declared a dividend, has an average analyst rating of "Moderate Buy" with a target price of $386.28.
Silvant Capital Management LLC Invests $12 Million in Axon Enterprise, Inc $AXON
Silvant Capital Management LLC has acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON), purchasing 21,406 shares valued at approximately $12 million during the second quarter. This investment highlights continued institutional interest in Axon, with other hedge funds also adjusting their stakes. The company's stock has recently seen a pullback, and insiders have sold shares, while analysts have issued various ratings, with a consensus of "Moderate Buy."
Silvant Capital Management LLC Makes New $5.32 Million Investment in Molina Healthcare, Inc $MOH
Silvant Capital Management LLC has made a new investment of $5.32 million in Molina Healthcare, Inc. (NYSE:MOH) by acquiring 23,245 shares. Other institutional investors have also adjusted their holdings in Molina Healthcare, with a significant portion of the stock now owned by institutional investors. Molina Healthcare's stock recently traded at $197.69, and the company reported earnings that beat analyst estimates in its last quarterly report.
Paralel Advisors LLC Invests $5.29 Million in Humana Inc. $HUM
Paralel Advisors LLC recently acquired a new stake of 13,322 shares in Humana Inc. (NYSE:HUM) worth approximately $5.29 million during the second quarter, making it the 23rd biggest position in their holdings. Humana's latest quarterly earnings surpassed expectations, with EPS of $7.61 and revenue of $40.89 billion, showing a 26.2% year-over-year increase. Despite mixed analyst sentiment resulting in a consensus "Hold" rating and a target price of $395.22, institutional investors collectively own 92.38% of the company's stock.
XY Capital Ltd Buys Shares of 36,769 ResMed Inc. $RMD
XY Capital Ltd acquired 36,769 shares of ResMed Inc. (NYSE:RMD) during the second quarter, making it their fourth-largest holding and representing 6.9% of their portfolio, valued at approximately $7.17 million. ResMed recently reported strong quarterly results, exceeding expectations with earnings of $2.95 per share and revenue of $1.46 billion, an 8.6% increase year-over-year. The company also increased its quarterly dividend to $0.66 per share, while analysts maintain a consensus "Hold" rating with a target price of $239.38.
Arrowhead Pharmaceuticals director sells $173,920 in stock
A director at Arrowhead Pharmaceuticals, Adeoye Y. Olukotun, sold 2,000 shares of company stock for $173,920. The sale occurred on August 18, 2026, when the stock was trading near its 52-week high, after a significant 322% return over the past year. Despite the stock's performance, InvestingPro analysis suggests it may be overvalued.
Ascentage Pharma (SEHK:6855) Stock Faces Rising Losses Despite Revenue Growth
Ascentage Pharma (SEHK:6855) reported H1 2026 results showing a 29% revenue increase to ¥302.2m, primarily from product sales, alongside a widened net loss of ¥816.7m. Despite commercial progress with two approved products in China and a broad late-stage pipeline, the company's trailing 12-month loss reached ¥1.47b, raising concerns about funding risks and its high 16.1x price-to-sales multiple compared to peers. The company has a cash balance of US$279.4m with a stated runway until the end of 2027.
Paralel Advisors LLC Buys Shares of 10,293 ResMed Inc. $RMD
Paralel Advisors LLC has acquired 10,293 shares of ResMed Inc. (NYSE:RMD) stock, valued at approximately $2.0 million, marking a new position for the institutional investor. Other major investors, including Hsbc Holdings PLC and Goldman Sachs Group Inc., also increased their holdings in ResMed. Despite mixed analyst ratings with an average "Hold," ResMed reported strong Q2 earnings, surpassing EPS estimates and increasing revenue by 8.6% year-over-year, alongside a quarterly dividend hike.
Paralel Advisors LLC Purchases Shares of 4,883 HCA Healthcare, Inc. $HCA
Paralel Advisors LLC has acquired 4,883 shares of HCA Healthcare, Inc., valued at approximately $1.9 million, bringing the total institutional ownership to 62.73%. Despite some analyst price target reductions, the stock holds a "Moderate Buy" consensus rating with a target of $462.64, significantly above its recent trading price. HCA Healthcare also reported strong quarterly earnings, beating expectations with $7.59 adjusted EPS and $20.23 billion in revenue, and declared a quarterly dividend of $0.78 per share.
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Virtus Advisers LLC has made a new investment in ACADIA Pharmaceuticals Inc., purchasing over 44,000 shares valued at approximately $1.12 million. Other institutional investors like BlackRock and Norges Bank also significantly increased their stakes. Despite insider selling, analysts maintain a "Moderate Buy" consensus for ACADIA Pharmaceuticals, which recently beat earnings estimates.
Silvant Capital Management LLC Invests $11.93 Million in Cencora, Inc. $COR
Silvant Capital Management LLC has acquired a new position in Cencora, Inc. (NYSE:COR) during the second quarter, purchasing 42,144 shares valued at approximately $11.93 million. This investment comes as several other institutional investors have also adjusted their holdings in Cencora. Analysts maintain a "Moderate Buy" rating for Cencora, with an average target price of $370.85, following strong earnings results and a declared quarterly dividend.
Paralel Advisors LLC Purchases New Position in Cencora, Inc. $COR
Paralel Advisors LLC has acquired a new position in Cencora, Inc. (NYSE:COR), purchasing 7,354 shares valued at approximately $2.08 million in the second quarter. Institutional investors hold a significant 97.52% of the company's stock, with several other major firms also increasing or establishing stakes. Wall Street analysts maintain a "Moderate Buy" consensus rating for Cencora, with an average price target of $370.85, following strong earnings, revenue beats, a $0.60 quarterly dividend, and a $2 billion share repurchase program authorization.
Portfolio Design Labs LLC Makes New Investment in Cencora, Inc. $COR
Portfolio Design Labs LLC has made a new investment in Cencora, Inc. (NYSE:COR), purchasing 3,453 shares valued at approximately $977,000 during the second quarter. This new stake highlights continued institutional interest in Cencora, with various other hedge funds and institutional investors also adjusting their holdings. The article details Cencora's stock performance, recent earnings, dividend announcements, insider activity, and analyst ratings, indicating a "Moderate Buy" consensus.
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026)
This article reports on an SEC filing by Allogene Therapeutics, Inc. (ALLO) dated August 21, 2026. The filing, a Form S-3, became effective on August 20, 2026, at 4:00 P.M. The article also provides a brief overview of the company's recent news and SEC filings, highlighting its market performance and a recent FDA RMAT designation.
Portfolio Design Labs LLC Takes $1.53 Million Position in Thermo Fisher Scientific Inc. $TMO
Portfolio Design Labs LLC has acquired a new position of 3,046 shares in Thermo Fisher Scientific Inc., valued at approximately $1.53 million, during the second quarter. This move is part of broader institutional interest, with several other firms also adjusting their stakes in the medical research company. Thermo Fisher Scientific has received a "Moderate Buy" consensus rating from analysts, with a target price of $619.41, and recently reported strong quarterly earnings and declared a quarterly dividend.
4,241 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Silvant Capital Management LLC
Silvant Capital Management LLC recently acquired 4,241 shares of Thermo Fisher Scientific Inc. (NYSE:TMO) valued at approximately $2.13 million. Other institutional investors also initiated positions, bringing total institutional ownership to 89.23%. Despite significant insider selling over the past 90 days, Thermo Fisher reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with an average price target of $619.41.
Silvant Capital Management LLC Takes Position in Stryker Corporation $SYK
Silvant Capital Management LLC has acquired 5,152 shares of Stryker Corporation (NYSE:SYK) valued at approximately $1.62 million in the second quarter. This move is part of broader institutional investor activity, with hedge funds and institutional investors collectively owning 77.09% of SYK. Stryker recently exceeded Q2 earnings and revenue expectations, reporting $3.69 EPS and $6.59 billion in revenue, and analysts maintain a "Moderate Buy" rating with a target price of $386.28.
Silvant Capital Management LLC Invests $1.68 Million in Cigna Group $CI
Silvant Capital Management LLC has acquired a new stake in Cigna Group, purchasing 6,105 shares valued at approximately $1.68 million during the second quarter. This investment comes as Cigna reported strong quarterly earnings, beating estimates with $7.78 per share and a 6.7% revenue increase year-over-year. The company also announced a quarterly dividend of $1.56 per share, reinforcing its financial health and attracting institutional interest, with collective ownership now at 86.99%.
5,422 Shares in HCA Healthcare, Inc. $HCA Bought by Silvant Capital Management LLC
Silvant Capital Management LLC acquired 5,422 shares of HCA Healthcare, Inc. valued at approximately $2.1 million during the second quarter. Institutional investors hold a significant 62.73% stake in the company. Despite recent price target reductions, HCA Healthcare maintains a consensus "Moderate Buy" rating from analysts, driven by strong quarterly earnings and revenue growth.
Alexandria Real Estate Equities (ARE) Completes $1 Billion Bond Deal, Is It Above Fair Value?
Alexandria Real Estate Equities (ARE) has completed a $1 billion bond offering, raising questions about its valuation. While the stock has seen short-term gains, its one-year total shareholder return is down, and it trades slightly above analyst targets. Simply Wall St's DCF model suggests the stock might be undervalued at $62.47, contrasting with a widely followed narrative that places its fair value at $51, making it appear 3.8% overvalued.
Mystic Asset Management Inc. Makes New Investment in Stryker Corporation $SYK
Mystic Asset Management Inc. has acquired a new stake in Stryker Corporation, purchasing 15,922 shares valued at approximately $5.01 million, making it their 23rd largest position. Other institutional investors have also adjusted their holdings in Stryker. Analysts have issued varied ratings and price targets for Stryker, with a consensus of "Moderate Buy" and a target of $386.28.
Mystic Asset Management Inc. Purchases New Stake in CVS Health Corporation $CVS
Mystic Asset Management Inc. has acquired a new position in CVS Health Corporation, purchasing over 30,000 shares valued at approximately $3.14 million. This move comes as other institutional investors have also adjusted their stakes in CVS Health, and analysts have recently issued "buy" and "overweight" ratings with increased price targets for the company. CVS Health recently reported strong quarterly earnings, exceeding consensus estimates, and announced a quarterly dividend.
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN
NewEdge Wealth LLC has initiated a new position in Biohaven Ltd. (NYSE:BHVN), acquiring 245,670 shares valued at approximately $3.66 million during the second quarter. This investment represents about 0.16% of Biohaven's stock. Other institutional investors have also adjusted their holdings in Biohaven, while analysts have issued a range of ratings, with a consensus of "Moderate Buy" and a target price of $21.75.
Steris stock holds above $230 as fiscal first-quarter earnings grow
Steris plc's stock is trading above $230 after the company reported increased fiscal first-quarter earnings and maintained its fiscal 2027 growth guidance. The company achieved adjusted earnings of $2.59 per share, a 10.7% increase year-over-year, and revenue of $1.49 billion, up 7.3%. Steris also saw its adjusted operating margin expand by 99 basis points, driven by higher volume, pricing actions, and a favorable mix of services and consumables, positioning it as a company balancing top-line expansion with cost control.
9,249 Shares in IQVIA Holdings Inc. $IQV Purchased by Wealthfront Advisers LLC
Wealthfront Advisers LLC recently acquired a new position of 9,249 shares in IQVIA Holdings Inc. (NYSE:IQV) valued at approximately $1.79 million. Other institutional investors also bought shares, with BlackRock Inc. making a significant purchase of $2.81 billion. IQVIA reported strong quarterly earnings, beating analyst estimates, and announced a $2 billion share buyback plan, indicating management's confidence in the stock.
SGL Investment Advisors Inc. Purchases New Position in ResMed Inc. $RMD
SGL Investment Advisors Inc. has acquired a new stake in ResMed Inc. (NYSE:RMD), purchasing 10,409 shares valued at approximately $2.29 million. Other institutional investors have also recently adjusted their positions in the company, which saw its stock open at $228.81 and has a market cap of $33.01 billion. ResMed recently reported strong earnings, exceeding analyst estimates, increased its quarterly dividend to $0.66 per share, and has a consensus "Hold" rating from analysts with a price target of $239.38.
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN
Wealthfront Advisers LLC has acquired a new stake worth approximately $4.37 million in Regeneron Pharmaceuticals (NASDAQ:REGN). Other institutional investors like BlackRock Inc. and Norges Bank have also significantly increased their holdings in the biopharmaceutical company. Regeneron recently announced a quarterly dividend and received FDA approval for Pasatru, a treatment for a rare genetic disorder, though some analysts suggest the approval's impact may already be priced into the stock.
NewEdge Wealth LLC Invests $2.44 Million in HCA Healthcare, Inc. $HCA
NewEdge Wealth LLC has invested approximately $2.44 million in HCA Healthcare, Inc. by acquiring 6,258 shares during the second quarter. HCA Healthcare reported strong quarterly earnings of $7.59 per share and revenue of $20.23 billion, surpassing analyst estimates, and declared a quarterly dividend of $0.78 per share. Despite a recent stock dip, analysts generally maintain a "Moderate Buy" rating with an average price target of $462.64, indicating potential upside from its current price of $406.33.
OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB
OVERSEA CHINESE BANKING Corp Ltd has acquired a new position in Biogen Inc. (NASDAQ:BIIB) stock, purchasing 18,867 shares valued at approximately $4.076 million in the second quarter. This move comes as other institutional investors have also modified their holdings, and analysts have issued a range of ratings from "Strong Buy" to "Sell" with a consensus "Moderate Buy" rating. Biogen recently exceeded earnings estimates, reporting $3.60 EPS against a consensus of $2.94, with revenue up 3.4% year-over-year.
Vise Technologies Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX
Vise Technologies Inc. recently acquired 7,882 shares of Vertex Pharmaceuticals (VRTX) valued at approximately $3.9 million, marking a new investment in the pharmaceutical company. Institutional investors now own 90.96% of Vertex, while analysts maintain a "Moderate Buy" rating with a consensus target price of $563.50. Despite narrowly missing earnings estimates with $4.73 EPS, Vertex reported strong quarterly revenue of $3.33 billion, exceeding expectations by 12.5% year-over-year.
Wealthfront Advisers LLC Acquires Shares of 6,440 West Pharmaceutical Services, Inc. $WST
Wealthfront Advisers LLC has acquired 6,440 shares of West Pharmaceutical Services, Inc. (NYSE:WST), valued at approximately $2.31 million, marking a new position for the firm. Other hedge funds have also increased their holdings in the medical instruments supplier. West Pharmaceutical Services reported strong Q2 earnings, beating analyst estimates, and has a "Moderate Buy" consensus rating from analysts with an average target price of $368.08.
OVERSEA CHINESE BANKING Corp Ltd Buys Shares of 26,540 Ventas, Inc. $VTR
OVERSEA CHINESE BANKING Corp Ltd has acquired a new stake of 26,540 shares in Ventas, Inc. (NYSE:VTR) valued at approximately $2.36 million during the second quarter. Other institutional investors have also adjusted their holdings in Ventas. The company's stock is trading at $92.82, with a market capitalization of $47.61 billion, and has received a "Moderate Buy" rating from analysts with a consensus target price of $98.00.
OVERSEA CHINESE BANKING Corp Ltd Invests $22.99 Million in Welltower Inc. $WELL
OVERSEA CHINESE BANKING Corp Ltd has acquired a new stake in Welltower Inc. (NYSE:WELL) worth approximately $22.99 million. This investment is part of a trend where several other hedge funds also increased their holdings in Welltower during the second quarter. The article also highlights recent analyst upgrades, Welltower's price performance, its latest earnings report which missed estimates, and an increase in its quarterly dividend.
PCM Encore LLC Buys Shares of 7,399 Gilead Sciences, Inc. $GILD
PCM Encore LLC acquired 7,399 shares of Gilead Sciences, Inc., valued at approximately $935,000, as part of broader institutional investment in the biopharmaceutical company. Analysts maintain a "Moderate Buy" consensus with an average price target of $158.04, following Gilead's strong quarterly revenue of $7.80 billion and a declared dividend of $0.82 per share. Despite some insider selling, the overall sentiment remains positive, driven by collaborations and pipeline developments.
